Investing.comCodex · 实盘不做把握 4/10
北京时间·🕒 发布 04:20:38时区推断·⟳ 抓取 04:21:38·⚡ 决策 08-04 12:41:08 +8h19m·84.8 天前
Haemonetics发布VASCADE MVP XL真实世界研究，1623名患者并发症率1.2%
研究显示VASCADE MVP XL在1623名患者中实现2分钟中位止血时间和92.5%当日出院率，临床证据偏正面。
📄 原文Investing.com↗ 原文
Haemonetics study shows safety data for vascular closure device
Dow posts first record close in nearly a month as stocks rally to kick off August BOSTON - Haemonetics Corporation (NYS…
不做 Haemonetics（HAE.US）
研究数据偏正面但不是新增FDA批准或采购订单，商业化增量未量化，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 medium ↗
关键理由
- 研究显示VASCADE MVP XL在1623名患者中实现2分钟中位止血时间和92.5%当日出院率，临床证据偏正面。
- FDA扩展标签已在2026年3月获批，本次更多是支持性论文发布而非新增监管准入。
主要风险
- 未披露新增销售、订单、报销或医院采购转化，难以量化短期收入增量。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 2,035 字
Dow posts first record close in nearly a month as stocks rally to kick off August
BOSTON - Haemonetics Corporation (NYSE:HAE) announced today the publication of a study evaluating its VASCADE MVP XL venous vascular closure system in large-bore sheath procedures.
The retrospective cohort study, conducted at Emory University and funded by Haemonetics, examined outcomes in 1,623 patients who received the device following large-bore venous access electrophysiology procedures. The procedures included pulsed field ablation for atrial fibrillation, left atrial appendage closure, or combined procedures using sheaths up to 17F outer diameter.
According to the press release statement, the study showed the system achieved median hemostasis time of 2 minutes and a 92.5% same-day discharge rate with median discharge time of 3.5 hours. The overall vascular complication rate was 1.2% with no surgical interventions required.
"With real-world clinical evidence from a large and diverse patient population, we continue to demonstrate the VASCADE MVP XL system’s consistent performance in large-bore venous closure," said Ken Crowley, Vice President and General Manager, Interventional Technologies at Haemonetics.
David B. De Lurgio, the study’s corresponding author and Medical Director of Electrophysiology at Emory Saint Joseph’s Hospital, noted that same-day discharge was achieved even with larger sheaths than historically used in device-based closure.
In March 2026, the FDA approved expanded labeling for the VASCADE MVP XL system to include procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths. The system is approved for use with various atrial fibrillation treatment technologies from Abbott, Boston Scientific, and Medtronic, as well as left atrial appendage closure solutions.
Haemonetics is a medical technology company focused on blood management and interventional technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOSTON - Haemonetics Corporation (NYSE:HAE) announced today the publication of a study evaluating its VASCADE MVP XL venous vascular closure system in large-bore sheath procedures.
The retrospective cohort study, conducted at Emory University and funded by Haemonetics, examined outcomes in 1,623 patients who received the device following large-bore venous access electrophysiology procedures. The procedures included pulsed field ablation for atrial fibrillation, left atrial appendage closure, or combined procedures using sheaths up to 17F outer diameter.
According to the press release statement, the study showed the system achieved median hemostasis time of 2 minutes and a 92.5% same-day discharge rate with median discharge time of 3.5 hours. The overall vascular complication rate was 1.2% with no surgical interventions required.
"With real-world clinical evidence from a large and diverse patient population, we continue to demonstrate the VASCADE MVP XL system’s consistent performance in large-bore venous closure," said Ken Crowley, Vice President and General Manager, Interventional Technologies at Haemonetics.
David B. De Lurgio, the study’s corresponding author and Medical Director of Electrophysiology at Emory Saint Joseph’s Hospital, noted that same-day discharge was achieved even with larger sheaths than historically used in device-based closure.
In March 2026, the FDA approved expanded labeling for the VASCADE MVP XL system to include procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths. The system is approved for use with various atrial fibrillation treatment technologies from Abbott, Boston Scientific, and Medtronic, as well as left atrial appendage closure solutions.
Haemonetics is a medical technology company focused on blood management and interventional technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。